# Sputum-derived Cellular Targets After Xolair (Omalizumab)

> **NCT02658877** · PHASE4 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 3 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02658877
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2018-07-19
- **Final completion:** 2018-07-19
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Difficulty recruiting subjects
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658877, "Sputum-derived Cellular Targets After Xolair (Omalizumab)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02658877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*